1. Ali IU, Campbell G, Lidereau R, Callahan R. Amplification of c-erbB-2 and aggressive human breast tumors? Science 1988; 240 (4860): 1795–6.
2. Allegra CJ, Jessup JM, Somerfield MR et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 2009; 27 (12): 2091–6.
3. Baselga J, Carbonell X, Castaneda-Soto NJ et al. Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol 2005; 23 (10): 2162–71.
4. Beerli RR, Wels W, Hynes NE. Intracellular expression of single chain antibodies reverts ErbB-2 transformation. Biol Chem 1994; 269 (39): 23931–6.
5. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000; 6 (4): 443–6.
6. Cobleigh MA, Vogel CL, Tripathy D et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17 (9): 2639–48.
7. Coussens L, Yang-Feng TL, Liao YC et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 1985; 230 (4730): 1132–9.
8. Force T, Krause DS, Van Etten RA. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer 2007; 7 (5): 332–44.
9. Fountzilas G, Razis E, Tsavdaridis D et al. Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: a retrospective analysis of 80 cases by the hellenic cooperative oncology group. Clin Breast Cancer 2003; 4 (2): 120–5.
10. Gelmon KA, Mackey J, Verma S et al. Use of trastuzumab beyond disease progression: observations from a retrospective review of case histories. Clin Breast Cancer 2004; 5 (1): 52–62.
11. Gennari R, Menard S, Fagnoni F et al. Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin Cancer Res 2004; 10 (17): 5650–5.
12. Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol 2008; 19 (9): 1523–9.
13. Guarneri V, Frassoldati A, Bruzzi P et al. Multicentric, randomized phase III trial of two different adjuvant chemotherapy regimens plus three versus twelve months of trastuzumab in patients with HER2-positive breast cancer (Short-HER Trial; NCT00629278). Clin Breast Cancer 2008; 8 (5): 453–6.
14. Hudis CA. Trastuzumab–mechanism of action and use in clinical practice. N Engl J Med 2007; 357 (1): 39–51.
15. Imyanitov EN, Chernitsa OI, Serova OM, Knyazev PG. Rare occurrence of amplification of HER-2 (erbB-2/neu) oncogene in ovarian cancer patients. Eur J Cancer 1992; 28A (6–7): 1300.
16. Imyanitov EN, Chernitsa OI, Serova OM et al. Amplification of HER-2(erbB-2/neu) oncogene as the most significant prognostic factor in a group of Russian breast cancer patients. Neoplasma 1993; 40 (1): 35–9.
17. Joensuu H, Kellokumpu-Lehtinen PL, Bono P et al. FinHer Study Investigators. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006; 354 (8): 809–20.
18. Kawaguchi Y, Kono K, Mimura K et al. Cetuximab induce antibody-dependent cellular cytotoxicity against EGFR-expressing esophageal squamous cell carcinoma. Int J Cancer 2007; 120 (4): 781–7.
19. Krug LM, Miller VA, Patel J et al. Randomized phase II study of weekly docetaxel plus trastuzumab versus weekly paclitaxel plus trastuzumab in patients with previously untreated advanced nonsmall cell lung carcinoma. Cancer 2005; 104 (10): 2149–55.
20. Lewis GD, Figari I, Fendly B et al. Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies. Cancer Immunol Immunother 1993; 37 (4): 255–63.
21. Nahta R, Esteva FJ. HER2 therapy: molecular mechanisms of trastuzumab resistance. Breast Cancer Res 2006; 8 (6): 215.
22. Nielsen DL, Andersson M, Kamby C. HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors. Cancer Treat Rev 2009; 35 (2): 121–36.
23. Repka T, Chiorean EG, Gay J et al. Trastuzumab and interleukin-2 in HER2-positive metastatic breast cancer: a pilot study. Clin Cancer Res 2003; 9 (7): 2440–6.
24. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353 (16): 1673–84.
25. Sauter G, Lee J, Bartlett JM et al. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol 2009; 27 (8): 1323–33.
26. Scandinavian Breast Group Trial 9401, Tanner M, Isola J, Wiklund T et al. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401. J Clin Oncol 2006; 24 (16): 2428–36.
27. Schechter AL, Stern DF, Vaidyanathan L et al. The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature 1984; 312 (5994): 513–6.
28. Semba K, Kamata N, Toyoshima K, Yamamoto T. A v-erbB-related protooncogene, c-erbB-2, is distinct from the c-erbB-1/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma. Proc Natl Acad Sci USA 1985; 82 (19): 6497–501.
29. Slamon DJ, Clark GM, Wong SG et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235 (4785): 177–82.
30. Slamon DJ, Clark GM. Amplification of c-erbB-2 and aggressive human breast tumors? Science 1988; 240 (4860): 1796–8.
31. Slamon DJ, Godolphin W, Jones LA et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244 (4905): 707–12.
32. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344 (11): 783–92.
33. Tripathy D, Slamon DJ, Cobleigh M et al. Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol 2004; 22 (6): 1063–70.
34. Umemura S, Osamura RY, Akiyama F et al. What causes discrepancies in HER2 testing for breast cancer? A Japanese ring study in conjunction with the global standard. Am J Clin Pathol 2008; 130 (6): 883–91.
35. Valabrega G, Montemurro F, Aglietta M. Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol 2007; 18 (6): 977–84.
36. Van Cutsem E, Kang Y, Chung H et al. Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). J Clin Oncol 27: 18s, 2009 (suppl: ASCO Meeting Abstracts, Jun 2009), abstr LBA4509.
37. von Minckwitz G, du Bois A, Schmidt M et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03–05 study. J Clin Oncol 2009; 27 (12): 1999–2006.
38. Weinstein IB, Joe A. Oncogene addiction. Cancer Res 2008; 68 (9): 3077–80.
39. Wolmark N, Yothers G, O'Connell MJ et al. A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: Results of NSABP Protocol C-08 J Clin Oncol 27: 18s, 2009 (suppl: ASCO Meeting Abstracts, Jun 2009; abstr LBA4.
40. Zhou D, Battifora H, Yokota J et al. Association of multiple copies of the c-erbB-2 oncogene with spread of breast cancer. Cancer Res 1987; 47 (22): 6123–5.

Е.Н.Имянитов

НИИ онкологии им. Н.Н.Петрова, Санкт-Петербург